Rates of Emergence of HIV Drug Resistance in Resource-Limited Settings: A Systematic Review
- 1 January 2013
- journal article
- review article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 18 (1), 115-123
- https://doi.org/10.3851/imp2437
Abstract
Background: The increasing availability of antiretroviral therapy (ART) has improved survival and quality of life for many infected with HIV, but can also engender drug resistance. This review summarizes the available information on drug resistance in adults in resource-limited settings. Methods: The online databases PubMed and Google Scholar, pertinent conference abstracts and references from relevant articles were searched for publications available before November 2011. Data collected after ART rollout were reviewed. Results: A total of 7 studies fulfilled the criteria for the analysis of acquired drug resistance and 22 fulfilled the criteria for the analysis of transmitted drug resistance (TDR). Acquired resistance was detected in 7.2% of patients on ART for 6–11 months, 11.1% at 12–23 months, 15.0% at 24-35 months, and 20.7% at ≥36 months. Multi-class drug resistance increased steadily with time on ART. The overall rate of TDR in all resource-limited countries studied was 6.6% (469/7,063). Patients in countries in which ART had been available for ≥5 years were 1.7x more likely to have TDR than those living in a country where ART had been available for <5 years ( P<0.001). The reported prevalence of TDR was 5.7% (233/4,069) in Africa, 7.6% (160/2,094) in Asia and 8.4% (76/900) in Brazil. Conclusions: The emergence of drug resistance following access to ART in resource-limited settings resembles what was seen in resource-rich countries and highlights the need for virological monitoring for drug failure, drug resistance testing and alternative drug regimens that have proven beneficial in these resource-rich settings.This publication has 55 references indexed in Scilit:
- HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational studyThe Lancet Infectious Diseases, 2011
- HIV-1 Drug Resistance Mutations Among Antiretroviral-Naive HIV-1-Infected Patients in Asia: Results From the TREAT Asia Studies to Evaluate Resistance-Monitoring StudyClinical Infectious Diseases, 2011
- Prevalence of Genotypic Resistance to Antiretroviral Drugs in Treatment-Naive Youths Infected with Diverse HIV Type 1 Subtypes and Recombinant Forms in Dar es Salaam, TanzaniaAIDS Research and Human Retroviruses, 2011
- Drug Resistance Mutations in Drug-Naive HIV Type 1 Subtype C-Infected Individuals from Rural MalawiAIDS Research and Human Retroviruses, 2011
- High HIV Type 1 Group MpolDiversity and Low Rate of Antiretroviral Resistance Mutations Among the Uniformed Services in Kinshasa, Democratic Republic of the CongoAIDS Research and Human Retroviruses, 2011
- Transmitted HIV Type 1 Drug Resistance Among Individuals with Recent HIV Infection in East and Southern AfricaAIDS Research and Human Retroviruses, 2011
- Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in HaitiThe New England Journal of Medicine, 2010
- Cost‐Effectiveness of Laboratory Monitoring in Sub‐Saharan Africa: A Review of the Current LiteratureClinical Infectious Diseases, 2010
- Improved Virological Outcomes in British Columbia Concomitant with Decreasing Incidence of HIV Type 1 Drug Resistance DetectionClinical Infectious Diseases, 2010
- HIV‐1 reverse transcriptase drug‐resistance mutations in chronically infected individuals receiving or naïve to HAART in CameroonJournal of Medical Virology, 2009